Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease

European Heart Journal

Volumn 31, Issue 21, 2010, Pages 2601-2613

  Goto, Shinya ^a   Ogawa, Hisao ^b   Takeuchi, Masaru ^c   Flather, Marcus D ^d   Bhatt, Deepak L ^e  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^c EISAI CO LTD   (Japan)

^d ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute coronary syndrome; Atherothrombosis; Coronary artery disease; E5555; PAR 1; Thrombin

Indexed keywords

ANTICOAGULANT AGENT; CLOPIDOGREL; E 5555; PLACEBO; PROTEINASE ACTIVATED RECEPTOR 1; TICLOPIDINE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; JAPANESE; LIVER FUNCTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT; T WAVE; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; DRUG-INDUCED LIVER INJURY; FEMALE; HEMORRHAGE; HUMANS; IMINES; LONG QT SYNDROME; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECEPTOR, PAR-1;

EID: 78149355554     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq320     Document Type: Article

References (31)

1. Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, Nakamura H, Okubo K, Iida M. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke 2003;34: 2349-2354.
2. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Röther J, Wilson PWF. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-189.
3. Steg PG, Bhatt DL, Wilson PWF, D'Agostino R, Ohman EM, Röther J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297:1197-1206.
4. Yamazaki T, Goto S, Shigematsu H, Shimada K, Uchiyama S, Nagai R, Yamada N, Matsumoto M, Origasa H, Bhatt DL, Steg PG, Ikeda Y. Prevalence, awareness and treatment of cardiovascular risk factors in patients at high risk of atherothrombo-sis in Japan. Circ J 2007;71:995-1003.
5. Hoshiba Y, Hatakeyama K, Tanabe T, Asada Y, Goto S. Co-localization of von Willebrand factor with platelet thrombi, tissue factor and platelets with fibrin, and consistent presence of inflammatory cells in coronary thrombi obtained by an aspiration device from patients with acute myocardial infarction. J Thromb Haemost 2006;4:114-120.
6. Jennings LK. Role of platelets in atherothrombosis. Am J Cardiol 2009;103:4-10.
7. Angiolillo J, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 2010;31:17-28.
8. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007;100:1261-1275.
9. Goto S. Understanding the mechanism and prevention of arterial occlusive thrombus formation by anti-platelet agents. Curr Med Chem Cardiovasc Hematol Agents 2004;2:149-156. (Pubitemid 38854976)
10. Bhatt DL. Diffuse coronary disease and atherothrombosis: a rationale for long-term therapy to prevent recurrent ischemic events. J Invasive Cardiol 2003; 15(Suppl. B):3B-9B; discussion 9B-10B.
11. Awtry EH, Loscalzo J. Aspirin. Circulation 2000;101:1206-1218.
12. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopido-grel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
13. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association
14. Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). Circulation 2007;116:e148-e304.
15. Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 2006;113:2363-2372.
16. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407:258-264.
17. Hamilton JR. Protease-activated receptors as targets for antiplatelet therapy. Blood Rev 2009;23:61-65.
18. Chackalamannil S, Xia Y. Thrombin receptor (PAR-1) antagonists as novel antith-rombotic agents. Expert Opin Ther Pat 2006;16:493-505.
19. Serebruany VL, Kogushi M, Dastros-Pitei D, Flather M, Bhatt DL. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Thromb Haemost 2009;102:111-119.
20. Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A, Ziada KM, Berman G, Strony J, Joseph D, Mahaffey KW, Werf FV, Veltri E, Harrington RA. Safety and tolerability of SCH530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomized, double-blind, placebo-controlled phase II study. Lancet 2009;373:919-928.
21. Goto S, Yamaguchi T, Ikeda Y, Kato K, Yamaguchi H, Jensen P. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb 2010; 17:156-164.
22. Létienne R, Leparq-Panissié A, Bocquet A, Calmettes Y, Culié C, Le Grand B. PAR1 antagonist mediated antithrombotic activity in extracorporeal arterio-venous shunt in the rat. Thromb Res 2010;125:257-261.
23. Mehta SR, Yusuf S. The clopidogrel in unstable angina to prevent recurrent events (CURE) trial programme: rationale, design, and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 2000;21:2033-2041.
24. Bovil EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, Feit F, Gore JM, Hillis LD, Lambrew CT, Leiboff R, Mann KG, Markis JE, Pratt CM, Sharkey SW, Sopko G, Tracy RP, Chesebro JH. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Ann Intern Med 1991;115:256-265.
25. Hirobe K, Terai T, Fujioka S, Goto K, Dohi S. Morbidity of myocardial infarction multicenter study in Japan (3M study)\-study design and event RATES for myo-cardial infarction and coronary death by age category in Japanese workers. Circ J 2005;69:767-773.
26. Reuben A. Hy's law. Hepatology 2004;39:574-578.
27. Wiviott D, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, Servi SD, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015. (Pubitemid 350106708)
28. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.
29. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
30. Bhatt DL. Intensifying platelet inhibition\-navigating between Scylla and Charyb-dis. N Engl J Med 2007;357:2078-2081.
31. 12 deficiency caused by a mutation in the translation initiation codon. J Thromb Haemost 2005;3:2315-2323.